Chris Boshoff: The European Medicines Agency (EMA) has accepted our application in collaboration with Astellas Pharma US and Merck for a combination therapy for advanced Urothelial Cancer

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn:

”The European Medicines Agency (EMA) has accepted our application in collaboration with Astellas Pharma US and Merck for a combination therapy for advanced Urothelial Cancer.

People living with bladder cancer in Europe face poor outcomes at the advanced stage, and innovative therapies are needed. This acceptance marks a significant milestone in our commitment to enhancing treatment options for people with bladder cancer.

Read more here.”

Source: Chris Boshoff/LinkedIn